This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
Plazomicin
INN: Plazomicin
Data updated: 2026-04-18
Available in:
🇩🇪🇬🇧🇵🇹
Form
—
Dosage
—
Route
—
Storage
—
About This Product
ATC Code
J01GB14
Source
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
KEGG
USDailyMed:Plazomicin
J01GB14(WHO)
US:℞-only
(2S)-4-Amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
1154757-24-0
42613186
DB12615
26390008
LYO9XZ250J
D10151as salt:D10655
ChEMBL1650559
EDS (PDBe,RCSB PDB)
DTXSID001031303
Interactive image
CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(=CC[C@H]3N)CNCCO)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O
InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1Key:IYDYFVUFSPQPPV-PEXOCOHZSA-N
Plazomicin, sold under the brand nameZemdri, is anaminoglycoside antibioticused to treat complicatedurinary tract infections.As of 2019 it is recommended only for those in whom alternatives are not an option.It is given byinjection into a vein.
Common side effects includekidney problems,diarrhea,nausea, andblood pressurechanges.Other severe side effects includehearing loss,Clostridioides difficile-associated diarrhea,anaphylaxis, andmuscle weakness.Use during pregnancy may harm the baby.Plazomicin works by decreasing the ability of bacteria to make protein.
Plazomicin was approved for medical use in the United States in 2018.It is on theWorld Health Organization's List of Essential Medicines.
⚠️ Warnings
• Plazomicin causes kidney damage, and patients must be monitored for their kidney function before and daily during the treatment with plazomicin; monitoring should be done particularly in patients with a family history of kidney disease or elderly patients who have a high risk of kidney dysfunction.
• Hearing loss is expected to occur during the treatment with plazomicin and patients must be carefully observed for any decline in hearing and should be treated appropriately.
• Injection vial of plazomicin should be inspected visually before administration for the presence of any visible particles and should be discarded if such things are present.
• Clostridium difficile-associated diarrhea (CDAD) may occur during plazomicin therapy and patients must be supported with fluid or electrolyte therapy. Never take an anti-diarrheal drug without a physician’s approval.
• Never give plazomicin to a patient with no suspected bacterial infection as it may cause the development of drug-resistance bacteria complicating the treatment schedule.
• Plazomicin affects the muscles and results in muscle weakness mainly in patients with a history of neuromuscular disorders such as
myasthenia gravis
.
